Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B
Clinical Gastroenterology and Hepatology · 2026-01 · 24 (1) · 121-130.e12
DOI: 10.1016/j.cgh.2025.04.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-01. Verfasst von Lisa M van Velsen und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, Netherlands. Electronic address: l.vanvelsen@erasmusmc.nl. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Liver Cirrhosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Foundation for Liver and Gastrointestinal Research.
Abstract (Originalsprache)
BACKGROUND & AIMS: The presence of metabolic comorbidities is associated with a higher risk of liver-related events in chronic hepatitis B (CHB) patients. However, the association between presence of metabolic comorbidities and the severity of biopsy-proven liver fibrosis is yet unknown. METHODS: Data from CHB patients from 2 tertiary clinics and 8 clinical trials was analyzed. We studied the association between presence of metabolic comorbidities with severity of liver fibrosis in untreated patients, and with fibrosis regression or progression in biopsies taken after initiation of antiviral therapy. RESULTS: We analyzed biopsies from 3179 untreated CHB patients. Median age was 37 years, 57.6% were hepatitis B e antigen positive, with median hepatitis B virus DNA of 7.30 logIU/mL. Overweight (29.4% vs 19.0%; P < .001), hypertension (40.7% vs 23.2%; P < .001), diabetes (42.2% vs 23.6%; P < .001), and dyslipidemia (42.9 vs 23.6%; P < .001) were associated with a higher risk of advanced fibrosis, with the highest risk observed in patients with multiple comorbidities. Findings were consistent in multivariable analysis (1 comorbidity: adjusted odds ratio [aOR], 1.115; ≥2 comorbidities: aOR, 1.627; P = .006). Regression to nonadvanced fibrosis, after treatment initiation, was more often observed in patients without metabolic comorbidities (43.1%), compared with patients with 1 (31.6%) or ≥2 comorbidities (17.0%) (P = .005). Findings were consistent in multivariable analysis (1 comorbidity: aOR, 0.792; ≥2 comorbidities: aOR, 0.260; P = .025). The risk of progression to advanced fibrosis was highest in patients with ≥2 comorbidities (14.3% vs 4.6%; P = .001). CONCLUSIONS: Presence of metabolic comorbidities in untreated CHB patients is associated with more severe liver fibrosis and, after initiation of antiviral therapy, with less fibrosis regression and a higher risk of fibrosis progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, Netherlands. Electronic address: l.vanvelsen@erasmusmc.nl.
- Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, Netherlands.
- Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada.
- Department of Medicine and Therapeutics and Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong SAR, China.
- NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand.
- Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
Förderung
- Gilead Sciences
- Foundation for Liver and Gastrointestinal Research
Zitieren
APA
van Velsen, L. M., Patmore, L. A., Feld, J. J., Chan, H. L. Y., Piratvisuth, T., Chien, R. N., Dongelmans, E. J., Pavlovic, V., Yee, L. J., Brouwer, W. P., Lau, A., Hansen, B. E., Buti, M., Xie, Q., Patel, K., Fung, S. K., Janssen, H. L. A., Sonneveld, M. J., & SONIC-B study group (2026). Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 24(1), 121-130.e12. https://doi.org/10.1016/j.cgh.2025.04.024
Vancouver
van Velsen LM, Patmore LA, Feld JJ, Chan HLY, Piratvisuth T, Chien RN, et al. Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology. 2026;24(1):121-130.e12. doi:10.1016/j.cgh.2025.04.024
BibTeX
@article{vanVelsen2026,
author = {van Velsen, Lisa M and Patmore, Lesley A and Feld, Jordan J and Chan, Henry L Y and Piratvisuth, Teerha and Chien, Rong-Nan and Dongelmans, Edo J and Pavlovic, Vedran and Yee, Leland J and Brouwer, Willem Pieter and Lau, Audrey and Hansen, Bettina E and Buti, Maria and Xie, Qing and Patel, Keyur and Fung, Scott K and Janssen, Harry L A and Sonneveld, Milan J and SONIC-B study group, SONIC-B study group},
title = {Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {1},
pages = {121--130.e12},
doi = {10.1016/j.cgh.2025.04.024}
}
EUVIMED